

PATENT

TECH CENTER 1600/2900
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 03 2002

TECH CENTER 1600/2900

Examiner: J. Reamer

Art Unit: 1614

RECEIVED

JUL 25 2001

Technology Center 2600

In re Application of
Hwang et al.

Serial No.: 09/353,461

Filed: July 13, 1999

Title: Method of Enhancing Bioavailability of
Fexofenadine and Its Derivatives

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, Washington, D.C. 20231, on

Date of Deposit

Signature

7-18-01

Patricia Dis...

FILE COPY

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

OCT 17 2002

Technology Center 2100

RECEIVED

JUL 20 2001

OFFICE OF PETITIONS

Sir:

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.


07/19/2001 SLUANG1 00000014 181982 09353462

02 FC:126 180.00 CH

M0

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☒ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,


Charlotte L. Barney, Reg. No. 35,060
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4551
Telefax (908) 231-2626

RECEIVED

JUL 20 2001

OFFICE OF PETITIONS

FORM PTO-1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

HMR 2013B

SERIAL NO.

09/353,462

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Hwang et al.

FILING DATE

July 13, 1999

GROUP

1614

RECEIVED

JUL 25 2001

Technology Center 2600

U.S. PATENT DOCUMENTS

EXAMINER INITIALS			DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLAS S	FILING DATE IF APPROPRIATE
		A1	4	2	5	4	1	2	9	3/3/81	Carr et al.			
		A2	4	2	8	5	9	5	7	8/25/81	Carr et al.			
		A3	5	5	7	4	0	4	5	11/12/96	Ortyl et al.			
		A4	5	5	6	7	5	9	2	10/22/96	Benet et al.			
		A5	5	6	6	5	3	8	6	9/9/97	Benet et al.			
		A6	5	7	1	6	9	2	8	2/10/98	Benet et al.			

RECEIVED

OCT 03 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	*		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION YES NO
		B1	9	6	4	0	1	9	2	12/19/96	WO			
		B2	9	5	2	0	9	8	0	8/10/95	WO			

RECEIVED

OCT 17 2002

Technology Center 2100

OTHER DOCUMENTS

EXAMINER INITIALS	*		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		C1	Germann et al, Cell Biology, Vol. 4, 1993; pp 63-76
		C2	Chang et al., Clinical Pharmacology & Therapeutics, March 1996 pp. 297-303
		C3	Saitoh et al., Pharmaceutical Research, Vol. 12, No. 9, 1995, pp 1304-1310
		C4	Nerurkar et al., Pharmaceutical Research, Vol. 13, No. 4, 1996, pp. 528-534
		C5	Cordon-Cardo et al., J. of Histochemistry and Cytochemistry, Vol. 38, No. 9, 1990, pp 1277-1287
		C6	Wacher et al, Molecular Carcinogenesis 13 1995, pp 129-134
		C8	Yun et al. Drug Metabolism and Disposition, Vol. 21, No. 3, 1993, pp. 403-409
		C9	Ling et al. Drug Metabolism and Disposition, Vol. 23, No. 6, 1995, pp. 631-636
		C10	Bendetti et al., Drug Metabolism Reviews, 1999; 31(3):665-717

RECEIVED

JUL 20 2001

OFFICE OF PETITIONS

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.